Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, plaatsen enz. Als u ons wilt ondersteunen dan kan dat via een al of niet anonieme donatie. Elk bedrag is welkom hoe klein ook. Klik hier als u ons wilt helpen kanker-actueel online te houden.  Wij zijn een ANBI organisatie dus uw donatie is in principe aftrekbaar voor de belasting

15 juni 2012: Bron: J Thorac Dis. 2011 June; 3(2): 105–114. doi:  10.3978/j.issn.2072-1439.2010.12.06

Immuuntherapie bij longkanker is lang door onderzoekers en artsen gezien als een bijna niet mogelijke vorm van behandelen. Toch zijn de afgelopen 10 jaar meerdere bewijzen geleverd dat incidenteel een bepaalde immuuntherapeutische aanpak succesvol kan zijn. Duitse onderzoekers analyseerden veel studies en publiceerden aan de hand daarvan een artikel dat de huidige stand van zaken weergeeft op het gebied van immuuntherapie bij niet-klein-cellige longkanker. Hier het abstract en onderaan een referentielijst. Op de website van Journal of Thoaric Disease kunt u het volledige studieverslag van genoemde studie gratis inzien.

Active-specific immunotherapy for non-small cell lung cancer

J Thorac Dis. 2011 Jun;3(2):105-14.

Active-specific immunotherapy for non-small cell lung cancer.

Source

Department of Surgery-Campus Grosshadern, Thoracic Surgery Center Munich, Laboratory of Clinical and Experimental Tumor Immunology, Ludwig-Maximilians-University, Munich, Germany;

Abstract

Non-small cell lung cancer constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide. Standard treatment for this devastating disease, such as systemic chemotherapy, has reached a plateau in effectiveness and comes with considerable toxicities. For all stages of disease fewer than 20% of patients are alive 5 years after diagnosis; for metastatic disease the median survival is less than one year. Until now, the success of active-specific immunotherapy for all tumor types has been sporadic and unpredictable. However, the active-specific stimulation of the host's own immune system still holds great promise for achieving non-toxic and durable antitumor responses. Recently, sipuleucel-T (Provenge(®); Dendreon Corp., Seattle, WA) was the first therapeutic cancer vaccine to receive market approval, in this case for advanced prostate cancer. Other phase III clinical trials using time-dependent endpoints, e.g. in melanoma and follicular lymphoma, have recently turned out positive. More sophisticated specific vaccines have now also been developed for lung cancer, which, for long, was not considered an immune-sensitive malignancy. This may explain why advances in active-specific immunotherapy for lung cancer lag behind similar efforts in renal cell cancer, melanoma or prostate cancer. However, various vaccines are now being evaluated in controlled phase III clinical trials, raising hopes that active-specific immunotherapy may become an additional effective therapy for patients with lung cancer. This article reviews the most prominent active-specific immunotherapeutic approaches using protein/peptide, whole tumor cells, and dendritic cells as vaccines for lung cancer.

PMID:
22263073
[PubMed - in process]

PMCID:
PMC3256502

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300. [PubMed]
2. Thun MJ, Henley S J, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006;98:691–9. [PubMed]
3. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–24. [PubMed]
4. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–91. [PubMed]
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8. [PubMed]
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22. [PubMed]
7. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol (Meeting Abstracts) 2009;s27:2.
8. Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol (Meeting Abstracts) 2009;s27:CRA9011.
9. Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch K-W, Fox BA, et al. Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist. 2010;15:112–8. [PMC free article] [PubMed]
10. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010;12:11–3. [PubMed]
11. O’Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer. 2000;83:853–7. [PMC free article] [PubMed]
12. O’Brien ME, Anderson H, Kaukel E, O’Byrne K, Pawlicki M, Von Pawel J, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol. 2004;15:906–14. [PubMed]
13. Stanford JL, Stanford CA, O’Brien ME, Grange JM. Successful immunotherapy with mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer. 2008;44:224–7. [PubMed]
14. Dranoff G, Jaffee E, Lazenbay A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–43. [PMC free article] [PubMed]
15. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624–30. [PubMed]
16. Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:326–31. [PubMed]
17. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, et al. Phase I/II trial of autologous tumour mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006;13:555–62. [PubMed]
18. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337–43. [PubMed]
19. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5:690–9. [PubMed]
20. Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003;12:493–502. [PubMed]
21. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3:735–44. [PubMed]
22. Acres B, Quoix E, Ramlau R, Lacoste G, Marie Bastien B, Tavernaro A, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol (Meeting Abstracts) 2009;s27:3027.
23. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, et al. Phase I study of the BLP25 (MUC1 Peptide) liposomale vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001;3:49–57. [PubMed]
24. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23:6674–81. [PubMed]
25. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. A mulit-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thor Oncol. 2007;2:s332–3.
26. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11:391–5. [PubMed]
27. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25:131–4. [PubMed]
28. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004;172:3289–96. [PubMed]
29. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 2007;s25:7554.
30. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009;10:371–4. [PubMed]
31. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-ß1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86:1712–9. [PubMed]
32. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24:4721–30. [PubMed]
33. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 1999;125:61–70. [PubMed]
34. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernández JC, González Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9:431–5. [PubMed]
35. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol. 2003;14:461–6. [PubMed]
36. Ramos TC, Vinageras E, Ferrer MC, Verdecia BG, Rupalé IL, Pérez LM, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther. 2006;5:145–9. [PubMed]
37. Gonzalez G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Hum Vaccin. 2007;3:8–13. [PubMed]
38. Garcia B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14:840–6. [PubMed]
39. Neninger Vinageras E, de la Torre A, Osorio Rodriquez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:1452–8. [PubMed]
40. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J, et al. Autologous dendritic cell vaccines for non-small cell lung cancer. J Clin Oncol. 2004;22:2808–15. [PubMed]
41. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007;57:365–72. [PMC free article] [PubMed]
42. Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, et al. Pilot study of 1650-G: A Simplified Cellular Vaccine for Lung Cancer. J Thorac Oncol. 2011;6:169–73. [PubMed]
43. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11:3017–24. [PubMed]
44. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer. 2010;11:228–37. [PubMed]
45. Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26:4418–25. [PubMed]
46. Morris JC, Vahanian N, Janik JE, Moses L, Tennant L, Pittaluga S, et al. Phase I study of an antitumor vaccination using α-(1,3) galactosyltransferase expressing allogeneic tumor cells in patients with refractory or recurrent non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 2005;s23:2586.
47. Raez LE, Cassileth PA, Schlesselmann JJ, Sridhar K, Padmanabhan S, Fisher EZ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:2800–7. [PubMed]
48. Neninger E, Diaz RM, de la Torre A, Rives R, Díaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther. 2007;6:145–50. [PubMed]
49. Ma J, Poehlein CH, Jensen SM, LaCelle MG, Moudgil TM, Rüttinger D, et al. Manipulating the host response to autologous tumor vaccines. Dev Biol (Basel) 2004;116:93–107. [PubMed]
50. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4. [PMC free article] [PubMed]
51. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9. [PMC free article] [PubMed]
52. Rüttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grützner S, et al. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med. 2007;5:43. [PMC free article] [PubMed]

Plaats een reactie ...

Reageer op "Immuuntherapie bij longkanker: overzicht van stand van zaken aan de hand van studieresultaten van laatste 10 jaar"


Gerelateerde artikelen